Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2001

01-04-2001 | Review

Pathological validation and significance of micrometastasis in sentinel nodes in primary breast cancer

Authors: Rajendra S Rampaul, Ahmed Miremadi, Sarah E Pinder, Andrew Lee, Ian O Ellis

Published in: Breast Cancer Research | Issue 2/2001

Login to get access

Abstract

In embracing a multidisciplinary approach to the management of patients with sentinel node biopsy in breast cancer, the pathologist task is to screen sentinel nodes for possible metastasis. The consequences of missing sentinel node micrometastasis can directly influence treatment strategies, and this screening therefore has to be performed with more attention than usual. There is presently great diversity in the histopathological work-up of sentinel nodes, with many centres employing additional techniques such as immunohistochemistry, reverse transcription polymerase chain reaction or flow cytometry in addition to routine haematoxylin and eosin staining. In this review, we address the pathological validation and significance of micrometastasis in sentinel node biopsy in primary breast cancer.
Literature
1.
Sapir O, Amromin GD: Obscure axillary lymph node metastasis in carcinoma of the breast. Cancer. 1948, 1: 238-241.CrossRef
2.
Pickren JW: Significance of occult metastasis: a study of breast cancer. Cancer. 1961, 14: 1266-1271.CrossRefPubMed
3.
4.
Turner RR, Ollila DW, Stern S, Giuliano AE: Optimal histopathologic examination of the sentinel lymph node for breast carcinoma staging. Am J Surg Pathol. 1999, 23: 263-267. 10.1097/00000478-199903000-00003.CrossRefPubMed
5.
Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, Feldman S, Kusminsky R, Gadd M, Kuhn J, Harlow S, Beitsch P: The sentinel node in breast cancer - a multicenter validation study. N Engl J Med. 1998, 339: 941-946. 10.1056/NEJM199810013391401.CrossRefPubMed
6.
Weaver DL, Krag DN, Ashikaga T, Harlow SP, O'Connell M: Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer. 2000, 88: 1099-1107. 10.1002/(SICI)1097-0142(20000301)88:5<1099::AID-CNCR22>3.0.CO;2-7.CrossRefPubMed
7.
O'Hea BJ, Hill AD, El-Shirbiny AM, Yeh SD, Rosen PP, Coit DG, Borgen PI, Cody HS: Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg. 1998, 186: 423-427. 10.1016/S1072-7515(98)00060-X.CrossRefPubMed
8.
Cody HS, Borgen PI: State-of-the-art approaches to sentinel node biopsy for breast cancer: study design, patient selection, technique, and quality control at Memorial Sloan-Kettering Cancer Center. Surg Oncol. 1999, 8: 85-91. 10.1016/S0960-7404(99)00029-8.CrossRefPubMed
9.
Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, Costa A, de Cicco C, Geraghty JG, Luini A, Sacchini V, Veronesi P: Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet. 1997, 349: 1864-1867. 10.1016/S0140-6736(97)01004-0.CrossRefPubMed
10.
Viale G, Bosari S, Mazzarol G, Galimberti V, Luini A, Veronesi P, Paganelli G, Bedoni M, Orvieto E: Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. Cancer. 1999, 85: 2433-2438. 10.1002/(SICI)1097-0142(19990601)85:11<2433::AID-CNCR18>3.0.CO;2-3.CrossRefPubMed
11.
Cserni G: Metastases in axillary sentinel lymph nodes in breast cancer as detected by intensive histopathological work up. J Clin Pathol. 1999, 52: 922-924.CrossRefPubMedPubMedCentral
12.
Zhang PJ, Reisner RM, Nangia R, Edge SB, Brooks JJ: Effectiveness of multiple-level sectioning in detecting axillary nodalmicrometastasis in breast cancer: a retrospective study with immunohistochemical analysis. Arch Pathol Lab Med. 1998, 122: 687-690.PubMed
13.
14.
Dowlatshahi K, Fan M, Bloom KJ, Spitz DJ, Patel S, Snider HC: Occult metastases in the sentinel lymph nodes of patients with early stage breast carcinoma: a preliminary study. Cancer. 1999, 86: 990-996. 10.1002/(SICI)1097-0142(19990915)86:6<990::AID-CNCR14>3.0.CO;2-D.CrossRefPubMed
15.
National Coordinating Group for Breast Screening Pathology:. Pathology Reporting in Breast Cancer Screening. Sheffield: National Health Service Breast Screening Programme,. 1995
16.
Fisher CJ, Boyle S, Burke M, Price AB: Intraoperative assessment of nodal status in the selection of patients with breast cancer for axillary clearance. Br J Surg. 1993, 80: 457-458.CrossRefPubMed
17.
Galimberti V, Zurrida S, Zucali P, Luini A: Can sentinel node biopsy avoid axillary dissection in clinically node-negative breast cancer patients?. Breast. 1998, 7: 8-10. 10.1016/S0960-9776(98)90043-1.CrossRef
18.
van Diest PJ, Torrenga H, Borgstein PJ, Pijpers R, Bleichrodt RP, Rahusen FD, Meijer S: Reliability of intraoperative frozen section and imprint cytological investigation of sentinel lymph nodes in breast cancer. Histopathology. 1999, 35: 14-18. 10.1046/j.1365-2559.1999.00667.x.CrossRefPubMed
19.
Veronesi U, Paganelli G, Viale G, Galimberti V, Luini A, Zurrida S, Robertson C, Sacchini V, Veronesi P, Orvieto E, De Cicco C, Intra M, Tosi G, Scarpa D: Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst. 1999, 91: 368-373. 10.1093/jnci/91.4.368.CrossRefPubMed
20.
Rubio IT, Korourian S, Cowan C, Krag DN, Colvert M, Klimberg VS: Sentinel lymph node biopsy for staging breast cancer. Am J Surg. 1998, 176: 532-535. 10.1016/S0002-9610(98)00264-5.CrossRefPubMed
21.
Noguchi S, Aihara T, Nakamori S, Motomura K, Inaji H, Imaoka S, Koyama H: The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Cancer. 1994, 74: 1595-1160.CrossRefPubMed
22.
Schoenfeld A, Luqmani Y, Smith D, O'Reilly S, Shousha S, Sinnett HD, Coombes RC: Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res. 1994, 54: 2986-2990.PubMed
23.
24.
Dowlatshahi K, Fan M, Snider HC, Habib FA: Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer. 1997, 80: 1188-1197. 10.1002/(SICI)1097-0142(19971001)80:7<1188::AID-CNCR2>3.0.CO;2-H.CrossRefPubMed
25.
International (Ludwig) Breast Cancer Study Group: Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet. 1990, 335: 1565-1568. 10.1016/0140-6736(90)91386-O.
26.
Neville AM, Price KN, Gelber RD, Goldhirsch A: Axillary node micrometastases and breast cancer [letter]. Lancet. 1991, 337: 1110-10.1016/0140-6736(91)91768-P.CrossRefPubMed
27.
Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S: A long term follow up study of survival in stage I (T1N0M0) and stage II (T1N0M0) breast carcinoma. J Clin Oncol. 1989, 7: 355-366.PubMed
28.
Fisher B, Wolmark N, Bauer M, Redmond C, Gebhardt M: The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet. 1981, 152: 765-772.PubMed
Metadata
Title
Pathological validation and significance of micrometastasis in sentinel nodes in primary breast cancer
Authors
Rajendra S Rampaul
Ahmed Miremadi
Sarah E Pinder
Andrew Lee
Ian O Ellis
Publication date
01-04-2001
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 2/2001
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr282

Other articles of this Issue 2/2001

Breast Cancer Research 2/2001 Go to the issue

Research article

Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth

Review

History of sentinel node and validation of the technique

Non-peer-reviewed research

Acid Phosphatase Activity in Human Breast Tumors

Commentary

Breast cancer chemoprevention: beyond tamoxifen

Non-peer-reviewed research

Overconfident Physician Opinion on the Effectiveness of BRCA1 Risk Reduction Measures

Meeting report

Hormones and Cancer 2000
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits